Fig. 8: Treatment with NVP-BEP800 improves survival of B-ALL PDX mice.

a Survival curves show that mice treated with NVP-BEP800 (10 mg/kg) survived longer than mice treated with vehicle, n = 8 mice per group. P value measured by Mantel–Haenszel test; ***P < 0.001. The timing of treatment is shown on the graphic. b Percentage of B-ALL cells (hCD45⁺ hCD19⁺) is measured by flow cytometry in PB at day 35 of the study, n = 5 mice per group. Data are shown as mean ± SD. P-value measured by two-tailed unpaired Student’s t test; ****P < 0.0001. c Mice are transplanted with bioluminescent B-ALL cells and treated with NVP-BEP800. Bioluminescence images of two mice per group, are taken at days 25 and 35 post-transplantation of bioluminescent B-ALL cells. At day 35, mice are sacrificed and bioluminescence images of their spleens and bones are taken. d Data show a reduction of B-ALL cells in BM of treated mice, as analyzed by flow cytometry to detect bioluminescent leukemic cells also expressing GFP and stained with hCD45 antibody. Data are shown as mean ± SD; n = 4 mice. P-value measured by two-tailed unpaired Student’s t test; ***P < 0.001. e Immunohistochemistry on bones sections shows a decrease in the amount of B-ALL cells (brown cells) in mice treated with NVP-BEP800. Counterstaining with Giemsa. Data is representative of four mice, magnification ×20, black scale bars represent 100 µm.